Articles

Tucatinib delivers in combination therapy

Seattle Genetics' tyrosine kinase inhibitor reduces disease progression in breast cancer patients when administered with trastuzumab and capecitabine
Written byKelsey Kaustinen
| 3 min read

BOTHELL, Wash.—In light of October being breast cancer awareness month, here's some good news out of Seattle Genetics for those suffering from this disease. The company reported positive top-line results this week from its HER2CLIMB trial—a randomized, double-blind, placebo-controlled, active comparator pivotal trial—of tucatinib. The trial evaluated tucatinib in combination with trastuzumab and capecitabine compared to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer who had previously received trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1).

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.